(PharmaNewsWire.Com, June 20, 2017 ) Gliosarcoma is a type of brain tumor that originates from glial cells. The tumor grows rapidly and symptom will vary depending on the exact location and size of the tumor. Most likely they may be headache, vomiting, cognitive problems, and drowsiness. Treatment of brain tumors depends upon the type and staging of the tumor, its size and position in the brain, as well as the age and other health problems of patient.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Gliosarcoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gliosarcoma (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gliosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gliosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 14, 10 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Gliosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Gliosarcoma (Oncology) . - The pipeline guide reviews pipeline therapeutics for Gliosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Gliosarcoma (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Gliosarcoma (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Gliosarcoma (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Gliosarcoma (Oncology) . - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Gliosarcoma (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Agenus Inc Bristol-Myers Squibb Company Celgene Corp DelMar Pharmaceuticals Inc ERC Belgium SA Merck & Co Inc Merrimack Pharmaceuticals Inc Millennium Pharmaceuticals Inc NewLink Genetics Corp Northwest Biotherapeutics Inc Novartis AG Nuo Therapeutics Inc Progenics Pharmaceuticals Inc Tragara Pharmaceuticals Inc
Number of Products under Development for Gliosarcoma, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Gliosarcoma - Pipeline by Agenus Inc, H1 2017 Gliosarcoma - Pipeline by Bristol-Myers Squibb Company, H1 2017 Gliosarcoma - Pipeline by Celgene Corp, H1 2017 Gliosarcoma - Pipeline by DelMar Pharmaceuticals Inc, H1 2017 Gliosarcoma - Pipeline by ERC Belgium SA, H1 2017 Gliosarcoma - Pipeline by Merck & Co Inc, H1 2017 Gliosarcoma - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017 Gliosarcoma - Pipeline by Millennium Pharmaceuticals Inc, H1 2017 Gliosarcoma - Pipeline by NewLink Genetics Corp, H1 2017 Gliosarcoma - Pipeline by Northwest Biotherapeutics Inc, H1 2017 Gliosarcoma - Pipeline by Novartis AG, H1 2017 Gliosarcoma - Pipeline by Nuo Therapeutics Inc, H1 2017 Gliosarcoma - Pipeline by Progenics Pharmaceuticals Inc, H1 2017 Gliosarcoma - Pipeline by Tragara Pharmaceuticals Inc, H1 2017 Gliosarcoma - Dormant Projects, H1 2017
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
